Revolution Medicines Inc

Market Cap

$35B

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Healthcare·Biotechnology·🇺🇸·NASDAQ

Stock Price

$148.49+$69.47 (+87.91%)

Jun 8, 2026

52W High $163.6852W Low $34.70

Company Details

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be...

CEO

—

IPO Date

Feb 13, 2020

Website

www.revmed.com

Key Metrics TTM

Revenue

-100.0% YoY

Net Income

-$1.4B

EPS (Diluted)

Free Cash Flow

-$1.1B

Revenue / Share

$0.00

Gross Margin

Operating Margin

Net Margin

FCF Margin

P/S

P/E

Earnings Reports

Q2 2026

Aug 5, 2026

PENDING

Q1 2026

May 6, 2026

FY 2025

Feb 25, 2026

Q4 2025

Feb 25, 2026

$0-100.0%

Q3 2025

Nov 5, 2025

Revenue & Profitability

Valuation

Operating Cash Flow

CapEx Spend

OpEx vs Revenue Growth (YoY)

Stock-Based Compensation

OpEx Breakdown

War Chest

Shares Outstanding

Revenue Per Employee

Revenue / Employee